Arkadij Elizarov
Principal investigator.
Medtech
Built from public records only: federal awards, patents, filings and papers.Is this you? Contact Noair Lab to claim this profile, correct it or hide it.
2015First federal award
$16.4MFederal grants as PI19 awards
1Patents grantedLatest Jun 4, 2019
34Papers2,931 citations
Federal awards and patents by year
AwardsPatents
19 awards · $16.4M
| Date | Agency | Award | Amount | Company |
|---|---|---|---|---|
| May 22, 2026 | NIH | SBIR Phase II Improving availability of ImmunoPET via automation of radio-synthesis and quality control of antibody-based HIV imaging PET tracers on a single platform. | $1.0M | Trace-Ability, Inc. |
| Apr 29, 2025 | NIH | SBIR Phase II Enabling nationwide AD PET imaging to support most efficient clinical trials by adoption of radically simplified and standardized quality control in commercial production of AD PET tracers. | $1.5M | Trace-Ability, Inc. |
| Mar 10, 2025 | NIH | SBIR Phase II Improving availability of ImmunoPET via automation of radio-synthesis and quality control of antibody-based HIV imaging PET tracers on a single platform. | $1.0M | Trace-Ability, Inc. |
| Aug 7, 2024 | NIH | SBIR Phase II Enabling nationwide AD PET imaging to support most efficient clinical trials by adoption of radically simplified and standardized quality control in commercial production of AD PET tracers. | $1.5M | Trace-Ability, Inc. |
| Jan 12, 2024 | NIH | SBIR Phase II Improving availability of ImmunoPET via automation of radio-synthesis and quality control of antibody-based HIV imaging PET tracers on a single platform. | $1.0M | Trace-Ability, Inc. |
| Jan 12, 2022 | NIH | SBIR Phase II Enabling nationwide AD PET imaging to support most efficient clinical trials by adoption of radically simplified and standardized quality control in commercial production of AD PET tracers. | $1.3M | Trace-Ability, Inc. |
| Sep 21, 2021 | NIH | SBIR Phase I Rapid pre-release sterility test for PET Drugs. | $168K | Trace-Ability, Inc. |
| Jan 25, 2021 | NIH | SBIR Phase II Enabling nationwide AD PET imaging to support most efficient clinical trials by adoption of radically simplified and standardized quality control in commercial production of AD PET tracers. | $1.3M | Trace-Ability, Inc. |
| Jul 9, 2020 | NIH | SBIR Phase II Development of completely automated quality control procedures for 4 PET Imaging tracers that will increase production throughput and lead to expanded diversity of PET imaging available to patients. | $811K | Trace-Ability, Inc. |
| Sep 18, 2019 | NIH | SBIR Phase I Improving availability of ImmunoPET via automation of radio-synthesis and quality control of antibody-based cancer imaging PET tracers on a single platform. | $300K | Trace-Ability, Inc. |
| Aug 1, 2019 | NIH | SBIR Phase II Development of completely automated quality control procedures for 4 PET Imaging tracers that will increase production throughput and lead to expanded diversity of PET imaging available to patients. | $1.5M | Trace-Ability, Inc. |
| Jul 25, 2019 | NIH | SBIR Phase II Development of completely automated quality control procedures for 4 PET Imaging tracers that will increase production throughput and lead to expanded diversity of PET imaging available to patients. | $690K | Trace-Ability, Inc. |
| Aug 8, 2018 | NIH | SBIR Phase II Development of completely automated quality control procedures for 4 PET Imaging tracers that will increase production throughput and lead to expanded diversity of PET imaging available to patients. | $232K | Trace-Ability, Inc. |
| Dec 11, 2017 | NIH | SBIR Phase II Analytical Methods for Automated Quality Control of Cancer PET Imaging Tracer - [F-18]FDG | $1.2M | Trace-Ability, Inc. |
| Dec 15, 2016 | NIH | SBIR Phase II Analytical Methods for Automated Quality Control of Cancer PET Imaging Tracer - [F-18]FDG | $860K | Trace-Ability, Inc. |
| Feb 29, 2016 | NSF | SBIR Phase II SBIR Phase II: Development of a simple device that eliminates bottlenecks in radiopharmaceutical production | $1.1M | Trace-Ability, Inc. |
| Feb 6, 2015 | NIH | SBIR Phase I Analytical Methods for Automated Quality Control of Cancer PET Imaging Tracer - [F-18]FDG | $150K | Trace-Ability, Inc. |
| Feb 6, 2015 | NIH | SBIR Phase I Analytical Methods for Automated Quality Control of Cancer PET Imaging Tracer - [F-18]FDG | $150K | Trace-Ability, Inc. |
| — | NIH | SBIR Phase II Development of a Benchtop Laboratory Platform for Amplicon Deep Sequencing | $748K | Trace-Ability, Inc. |
1 patents as inventor
- US 10309947Trace-Ability, Inc.Jun 4, 2019
Matched by the first inventor’s name and the patent’s company.
Peer ranks
Federal funding#19
Awards as PI#32
Patents#284
Companies
- Trace-Ability, Inc.Linked by awards · Medtech
Federal awards through Oct 21, 2026 and patents through Oct 20, 2026. Awards come from NIH, NSF and other agency records that name a principal investigator; DoD and NASA contract awards do not, so they are not shown here. Researchers are matched by name and company.